Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Cystic Fibrosis Pipeline Review, H2 2016 - 74 Companies & 137 Drug Molecules - Research and Markets

Research and Markets
Posted on: 28 Oct 16

Research and Markets has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2016" report to their offering.

'Cystic Fibrosis - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies

Universities.

'Cystic Fibrosis - Pipeline Review, H2 2016'; Cystic Fibrosis pipeline therapeutics constitutes close to 137 molecules. Out of which approximately 121 molecules are developed by Companies and remaining by the Universities/Institutes.

It also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 20, 22, 52 and 21 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 6, 6 and 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Cystic Fibrosis Overview
  3. Therapeutics Development
  4. Pipeline Products for Cystic Fibrosis - Overview
  5. Pipeline Products for Cystic Fibrosis - Comparative Analysis
  6. Cystic Fibrosis - Therapeutics under Development by Companies
  7. Cystic Fibrosis - Therapeutics under Investigation by Universities/Institutes
  8. Cystic Fibrosis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Cystic Fibrosis - Products under Development by Companies
  13. Cystic Fibrosis - Products under Investigation by Universities/Institutes
  14. Cystic Fibrosis - Companies Involved in Therapeutics Development
  • Actelion Ltd
  • Alaxia SAS
  • Arch Biopartners, Inc.
  • Arcturus Therapeutics, Inc.
  • Aridis Pharmaceuticals LLC
  • AstraZeneca Plc
  • Cilian AG
  • Concert Pharmaceuticals, Inc.
  • CRISPR Therapeutics
  • CSA Biotechnologies LLC
  • Cyclacel Pharmaceuticals, Inc.
  • DiscoveryBiomed, Inc.
  • Editas Medicine, Inc.
  • Eloxx Pharmaceuticals, Ltd.
  • ID Pharma Co., Ltd.
  • Immun System I.M.S. AB
  • Insmed Incorporated
  • Invion Limited
  • Kyorin Pharmaceutical Co., Ltd.
  • La Jolla Pharmaceutical Company
  • Lakewood-Amedex Inc
  • Lamellar Biomedical Ltd
  • Laurent Pharmaceuticals Inc.
  • OSE Immunotherapeutics
  • Paranta Biosciences Limited
  • Parion Sciences, Inc.
  • Pfizer Inc.
  • Progenra, Inc.
  • Savara Inc.
  • Shionogi & Co., Ltd.
  • Shire Plc
  • Synovo GmbH
  • TGV-Laboratories
  • The International Biotechnology Center (IBC) Generium
  • Verona Pharma Plc

For more information about this report visit http://www.researchandmarkets.com/research/4d8qd3/cystic_fibrosis

View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005491/en/

Business Wire
www.businesswire.com

Last updated on: 28/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.